NCT01534260: Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype |
|
|
| Completed | 1/2 | 37 | US | sorafenib, vorinostat and bortezomib | Hamid Sayar, Millennium Pharmaceuticals, Inc., Bayer, Merck Sharp & Dohme LLC | Acute Myeloid Leukemia | 08/16 | 02/17 | | |
